COMPARISON OF EFFICACY AND TOLERABILITY OF SPIRAPRIL AND NITRENDIPINE IN ARTERIAL-HYPERTENSION

被引：4

作者：

CARLSEN, JE ^{[1
]}

GALLOE, A ^{[1
]}

KOBER, L ^{[1
]}

LEIKERSFELDT, G ^{[1
]}

WINTHER, A ^{[1
]}

LUND, J ^{[1
]}

PETERSEN, LN ^{[1
]}

MCNAIR, A ^{[1
]}

机构：

[1] GLOSTRUP CTY HOSP,DEPT MED C,GLOSTRUP,DENMARK

来源：

DRUG INVESTIGATION | 1991年 / 3卷 / 03期

关键词：

D O I：

10.1007/BF03259560

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

In a double-blind randomised parallel group trial a new angiotensin-converting enzyme (ACE) inhibitor, spirapril, was compared to nitrendipine in 266 patients with hypertension (diastolic blood pressure 95 to 119mm Hg). Blood pressure was measured 24 hours after administration, and dose titration was performed every fourth week to achieve a diastolic blood pressure less-than-or-equal-to 90mm Hg. After 4 weeks' monotherapy with either nitrendipine 20mg once daily or spirapril 12mg once daily, the dose was increased to 40mg once daily and 24mg once daily, respectively, if goal blood pressure had not been achieved. After 8 weeks of monotherapy hydrochlorothiazide 12.5mg once daily could be added. Both treatments had a low response rate and the reduction in blood pressure was lower than expected. No significant difference was found in the reductions in blood pressures between the 2 treatment regimens. The effect of adding hydrochlorothiazide to spirapril was as expected, while the combination with nitrendipine only had a marginal extra effect on blood pressure. Significantly more patients in the nitrendipine group were withdrawn due to adverse events (27%) than in the spirapril group (7%). In conclusion, at the dosages used, nitrendipine and spirapril lower blood pressure to the same degree, but nitrendipine produces more adverse events. The addition of hydrochlorothiazide to nitrendipine cannot be recommended.

引用

页码：172 / 177

页数：6

共 14 条

[1]

Benjamin N., Phillips R.J.W., Robinson B.F., Verapamil and bendrofluazide in the treatment of hypertension: a controlled study of effectiveness alone and in combination, European Journal of Clinical Pharmacology, 34, pp. 249-253, (1988)

[2]

Brunner H.R., Waeber B., Nussberger J., Schaller M-D, Long-term clinical experiences with enalapril in essential hypertension, Journal of Hypertension, 1, pp. 103-107, (1983)

[3]

Carlsen J.E., Kober L., Blood pressure lowering effect and adverse events during treatment of arterial hypertension with isradipine and hydrochlorothiazide, Drug Investigation, 2, pp. 10-16, (1990)

[4]

Carlsen J.E., Kober L., Torp-Pedersen C., Johansen P., Relation between dose of bendrofluazide, antihypertensive effect and adverse biochemical effects, British Medical Journal, 300, pp. 975-978, (1990)

[5]

Cirillo V.J., Gomez H.J., Salonen J., Salonen R., Rissanen V., Et al., Lisinopril: dose-peak effect relationship in essential hypertension, British Journal of Clinical Pharmacology, 25, pp. 533-538, (1988)

[6]

Goa K.L., Sorkin E.M., Nitrendipine: an updated review, Drugs, 33, pp. 123-155, (1987)

[7]

Hampton J.R., Evidence suggesting that mild hypertension need not be treated, Journal of Hypertension, 4, (1986)

[8]

The report of the Joint National Committee on detection, evaluation and treatment of high blood pressure, Archives of Internal Medicine, 148, pp. 1023-1038, (1988)

[9]

Jurgensen H.J., Comparative effects of pinacidil and nifedipine in the treatment of arterial hypertension, Drugs, 36, pp. 67-69, (1988)

[10]

MRC trial of treatment of mild hypertension: principle results, British Medical Journal, 291, pp. 97-104, (1985)

← 1 2 →